Frontline Treatment Options for Patients With IDH2-Mutated AML


Shared insight on IDH-mutated acute myeloid leukemia and appropriate first-line treatment options in this setting.


Jorge E. Cortes, MD: Let me move to another category, and I’ll go back to Brian. What about patients with IDH mutations? We have IDH inhibitors, but in the frontline, we have some combinations approved and some therapy, but mostly with low-intensity therapy. What do you do for a fit patient with an IDH mutation where you would usually use a 3+7 [chemotherapy regimen]? Do you change your therapy in that setting for the front line in the fit patient?

Brian Andrew Jonas, MD, PhD: I’m not sure yet. I always want to call myself a dinosaur, meaning that I have been practicing long enough to earn that title. But perhaps I want to say in our general practice, we’re still using 7+3 for the IDH patients who are fit for induction, and not necessarily changing from that at this point. I will point out that [Eytan] Stein, [MD,] led a multicenter study that was published in Blood about a year ago that showed some interesting outcomes when you combined IDH inhibitors with 7+3 therapy in terms of promising response rates. I would like to see a randomized trial to change my practice there. In general, I would say 7+3 is still the way to go for the clear induction-eligible patients. We may have a separate discussion later for induction-ineligible patients, where I think there are some interesting debates can be had at this point with recent data. But I’d be curious to see if any of my other colleagues on the call here might have a different opinion.

Margaret T. Kasner, MD: I’ll jump in because I have a different practice. The truth is, and I already said it, I have a bias and it’s very anti-7+3, and I’m not sure where it came from to be perfectly honest. We have incorporated using FLAG-IDA [fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin] and venetoclax for fit IDH-mutated patients, with the idea that exposing them to venetoclax, based on the preponderance of data that we feel are available, is a better option for them. I have not adopted azacitidine, venetoclax for the patient who is fit for induction because I feel that’s an area that needs head-to-head comparison before I’m willing to change my practice. Maybe I’m a dinosaur in the idea that curing patients without chemotherapy currently seems impossible to me. Even if they’ve gotten azacitidine, venetoclax and then gone to transplant, they get chemotherapy in that setting. For those patients who can get it and who are fit, and who I’m going to move aggressively toward transplant, I use that combination up front until there are data to support a less aggressive approach even for the subset of patients. I’ll wait for the phase 3 data.

Transcript edited for clarity.

Related Videos
Video 14 - "Key Takeaways in HER2-Mutated NSCLC"
Video 13 - "Treatment Considerations in HER2-Mutated NSCLC"
Carrie L. Kitko, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Lori A. Leslie, MD
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer